Skip to main content
. 2019 Apr 29;8(6):2877–2885. doi: 10.1002/cam4.2204

Table 2.

The DFS and OS rate of 117 GC patients who underwent combined treatment with HIPEC

Aim of HIPEC Patients
(n)
Disease‐free survival Overall survival
1 year Median
(months)
P
logrank
1 year Median (months) P
logrank
Curative group 70 41.8% 10.0 <0.0001 53.8% 12.6 <0.0001
Adjuvant group 37 82.3% 28.0 91.7% 34.0
Palliative group 10 0% 2.5 0% 3.5

Abbreviations: GC, gastric cancer; HIPEC, hyperthermic intraperitoneal chemotherapy.